Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shenzhen Hepalink Pharmaceutical Group has entered a strategic distribution agreement with Zhejiang Yongtai Pharmaceutical to commercialize Gabapentin capsules in the U.S. market. This move aligns with Hepalink’s international expansion strategy, leveraging their established sales networks to tap into the $463 million U.S. market for Gabapentin. The partnership highlights Hepalink’s marketing capabilities and aims to boost its presence in overseas markets.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ‘Don’t Jump on Bandwagon,’ Says Top Investor About IonQ Stock
- ‘Time to Strike,’ Says Investor About AMD Stock
- Amazon’s (NASDAQ:AMZN) Return-to-Office Mandate Comes With Unexpected Issue
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
